Cerapedics announces first patients enrolled in IDE Clinical Trial of P-15L Bone Graft for transforaminal lumbar interbody fusion surgery
Proprietary synthetic small peptide technology (P-15) is being evaluated in patients across the U.S. with degenerative disk disease
Find out moreCerapedics announces closing of $22 million financing
Funding will accelerate commercialization and U.S. lumbar trial for i-FACTOR™ Peptide Enhanced Bone Graft
Find out moreCerapedics receives 2018 MedTech Breakthrough Award
Best New Surgical Technology Solution
Find out moreCerapedics announces results from IVANOS study of i-FACTOR Peptide Enhanced Bone Graft
Single-center randomized trial is measuring the efficacy of i-FACTOR in lumbar posterolateral spine surgery
Find out moreCerapedics announces i-FACTOR Peptide Enhanced Bone Graft adopted by more than 150 leading U.S. Hospitals
Rapid market adoption highlights advantages of synthetic small peptide technology, one of only two PMA approved bone graft supported by Level 1 human clinical data
Find out moreCerapedics announces appointment of Doug Kohrs to board of directors and names Antony Koblish Board Chair
Company announces exhibit at North American Spine Society 2017 annual meeting
Find out moreCerapedics Announces Publication of Two Year IDE Study Follow Up Data
Results published in Neurosurgery show peptide enhanced bone graft statistically superior to autograft in ACDF procedures at two years.
Find out moreOxford finance provides $20 Million senior debt facility to Cerapedics Inc.
Oxford Finance LLC (“Oxford”), an industryleading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term…
Find out moreCerapedics announces breakthrough technology agreement with Premier Inc.
Contract awarded for Breakthrough Technology: Bone Tissue Synthetic Implantable Products
Find out moreCerapedics receives Best New Technology Award for Spine Care at NASS Annual Meeting
Award recognizes i-FACTOR™ Peptide Enhanced Bone Graft based on the company’s synthetic small peptide (P-15) technology
Find out more
Welcome to Cerapedics
Choose your region
